Anti-TNF therapies: A comprehensive analysis of adverse effects associated with immunosuppression

Rheumatology International

Volumn 31, Issue 3, 2011, Pages 327-337

  Connor, Victoria ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse effects; Anti TNF; Biologics; Immunosuppresion; Rheumatology

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; ANTIVIRUS AGENT; DNA ANTIBODY; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT DISEASE; ADVERSE DRUG REACTION; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; APLASTIC ANEMIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; BLOOD TOXICITY; BRAIN DISEASE; CHILDHOOD DISEASE; CONGESTIVE HEART FAILURE; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HEALTH CARE PERSONNEL; HEART FAILURE; HEPATITIS B; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; MACROPHAGE ACTIVATION; MULTIPLE SCLEROSIS; NAUSEA; NEUROTOXICITY; OPTIC NEURITIS; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN REDNESS; TUBERCULOSIS; UVEITIS; VASCULITIS; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954448548     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1292-x     Document Type: Article

References (20)

1. F Atzeni P Sarzi-Puttini 2008 Autoantibody production in patients treated with anti-TNF-α Expert Rev Clin Immunol 4 2 275 280 1:CAS:528: DC%2BD1cXjtFKqu78%3D 10.1586/1744666X.4.2.275 20477056 (Pubitemid 351907759)
2. GS Deepe Jr RS Wallis 2006 Tumor necrosis factor-α inhibitors and granulomatous infectious Drug Discov Today Dis Mech 3 2 295 300 10.1016/j.ddmec.2006.06.006 (Pubitemid 44356305)
3. Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350(21):2167-2179, 2226
4. RS Wallis 2008 Tumor necrosis factor antagonists: structure, function, and tuberculosis risks Lancet Infect Dis 8 10 601 611 1:CAS:528: DC%2BD1cXht1Omsr%2FP 10.1016/S1473-3099(08)70227-5 18922482
5. S Kroesen AF Widmer A Tyndall P Hasler 2003 Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy Rheumatology 42 5 617 621 1:CAS:528:DC%2BD3sXjtlGnu7c%3D 10.1093/rheumatology/ keg263 12709536 (Pubitemid 37220869)
6. DE Furst R Wallis M Broder DO Beenhouwer 2006 Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Semin Arthritis Rheum 36 3 159 167 1:CAS:528:DC%2BD28XhtFOiu7nK 10.1016/j.semarthrit.2006.02.001 16884970 (Pubitemid 44691882)
7. RS Wallis S Ehlers 2005 Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab Semin Arthritis Rheum 34 5 SUPPL 34 38 1:CAS:528:DC%2BD2MXjtVyrtb4%3D 10.1016/j.semarthrit.2005.01.009 15852254
8. JP Callen 2007 Complications and adverse reactions in the use of newer biologic agents Semin Cutan Med Surg 26 1 6 14 1:CAS:528:DC%2BD2sXjvVyisLs%3D 10.1016/j.sder.2006.12.002 17349557 (Pubitemid 46349778)
9. Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clinl Exp Rheumatol 20(6 Suppl 28):S152-S157
10. Weinberg JM, Buchholz R (2006) TNF-alpha inhibitors, 1st edn. Birkh©Puser Verlag, Basel
11. Stone JH (2008) Tumor necrosis factor-alpha inhibitors: risk of bacterial, viral, and fungal infections. http://www.uptodate.com/online/content/ topic.do?topicKey=immuninf/8844. Accessed Oct 2008
12. SB Desai DE Furst 2006 Problems encountered during anti-tumor necrosis factor therapy Best Pract Res Clin Rheumatol 20 4 757 790 1:CAS:528: DC%2BD28Xps1Cntb8%3D 10.1016/j.berh.2006.06.002 16979537 (Pubitemid 44350122)
13. Stone JH (2008) Tumor necrosis factor-alpha inhibitors: risk of malignancy. http://www.uptodate.com/online/content/topic.do?topicKey=tx-rheum/ 14969. Accessed Oct 2008
14. WH Robinson MC Genovese LW Moreland 2001 Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor an antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 9 1977 1983 1:CAS:528:DC%2BD3MXpt12lsbg%3D 10.1002/1529-0131(200109)44:9<1977::AID- ART345>3.0.CO;2-6 11592357 (Pubitemid 33644038)
15. Stone JH (2008) Tumor necrosis factor-alpha inhibitors: an overview of adverse effects. http://www.uptodate.com/online/content/topic.do?topicKey=tx- rheum/12761&source=HISTORY. Accessed Oct 2008
16. SJ Lee A Kavanaugh 2005 Adverse reactions to biologic agents: focus on autoimmune disease therapies J Allergy Clin Immunol 116 4 900 905 1:CAS:528:DC%2BD2MXhtVyntLrJ 10.1016/j.jaci.2005.03.028 16210067 (Pubitemid 41400558)
17. MI Danila NM Patkar JR Curtis KG Saag GG Teng 2008 Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol 20 3 327 333 1:CAS:528:DC%2BD1cXkt1SlsL0%3D 10.1097/BOR.0b013e3282fb03d8 18388526 (Pubitemid 351483324)
18. P Balakumar M Singh 2006 Anti-tumor necrosis factor-α therapy in heart failure: future directions Basic Clin Pharmacol Toxicol 99 6 391 397 1:CAS:528:DC%2BD2sXhs1Wjuw%3D%3D 10.1111/j.1742-7843.2006.pto-508.x 17169118 (Pubitemid 44813905)
19. Stone JH (2008) Tumor necrosis factor-alpha inhibitors: induction of antibodies, autoantibodies, and autoimmune diseases. http://www.uptodate.com/ online/content/topic.do?topicKey=tx-rheum/14677. Accessed Oct 2008
20. RJ Moots A Taggart D Walker 2003 Biologic therapy in clinical practice: enthusiasm must be tempered by caution Rheumatology 42 5 614 616 1:STN:280:DC%2BD3s7ptVOnsg%3D%3D 12709535 (Pubitemid 37220868)